Form 4: Boston Scientific EVP and CFO Daniel J. Brennan Executes Stock Sales and Option Exercises
SEC Form 4
Daniel J. Brennan, EVP and CFO of Boston Scientific, reports multiple transactions involving the sale of common stock and the exercise of stock options, executed under a pre-established Rule 10b5-1 trading plan.
Summary
- Daniel J. Brennan, the EVP and CFO of Boston Scientific, filed a Form 4 detailing changes in beneficial ownership.
- On February 18, 2025, Brennan sold 2,900 shares of common stock at a weighted average price of $104.0752 and 14,630 shares at a weighted average price of $104.673.
- On February 19, 2025, Brennan exercised stock options to acquire 18,533 shares at $24.55, 16,865 shares at $17.26, 15,642 shares at $27.09, and 9,483 shares at $40.12.
- Also on February 19, 2025, Brennan sold 67,333 shares at a weighted average price of $105.2398.
- These transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
- Following these transactions, Brennan directly owns 225,808 shares of common stock.
- Brennan also holds options to purchase 31,285 shares at $27.09, 37,934 shares at $40.12, 0 shares at $17.26 and 37,067 shares at $24.55.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often used for personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are common across the medical device industry.
- Companies like Medtronic, Abbott, and Stryker also have executives who regularly exercise stock options and sell shares.
- The specific amounts and timing of these transactions vary based on individual compensation packages and financial planning strategies.
Stakeholder Impact
- The stock sales may have a minor impact on the stock price, but the pre-planned nature of the transactions mitigates concerns about insider trading.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 08/26/2024 | Date of adoption of the Rule 10b5-1 trading plan. |
| 02/18/2025 | Date of common stock sales. |
| 02/19/2025 | Date of stock option exercises and common stock sales. |
| 02/15/2019 | First anniversary of the grant date for options vesting in four equal annual installments. |
| 02/21/2020 | First anniversary of the grant date for options vesting in four equal annual installments. |
| 02/22/2017 | First anniversary of the grant date for options vesting in four equal annual installments. |
| 02/28/2018 | First anniversary of the grant date for options vesting in four equal annual installments. |
| 02/15/2028 | Expiration date of stock options. |
| 02/21/2029 | Expiration date of stock options. |
| 02/22/2026 | Expiration date of stock options. |
| 02/28/2027 | Expiration date of stock options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Stock Sale, Daniel J. Brennan, Boston Scientific, BSX, EVP, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.